DocDollars

Regeneron Pharmaceuticals, Inc.

NY · United States · Reporting entity ID 100000000069

Total reported 2019–2025
$1.15B
#16 of 2,960 reporting companies — 1.4% of all reported industry payments
$51.0M in general payments across 24,746 records, plus $1.09B in research funding across 206,458 records.

How it breaks down

General payments $50,991,821
Research funding $1,094,125,708

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Regeneron Pharmaceuticals, Inc. reported $1.15B to US doctors and teaching hospitals from 2019 to 2025, ranking #16 of 2,960 reporting companies. 96% of that was research funding and 4% general payments such as consulting, speaking, food and travel. 24,746 general payment records and 206,458 research records were filed.

Common questions about Regeneron Pharmaceuticals, Inc.

How much has Regeneron Pharmaceuticals, Inc. paid US doctors?

Regeneron Pharmaceuticals, Inc. reported $1,145,117,529 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $50,991,821 in general payments, $1,094,125,708 in research funding.

How does Regeneron Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #16 of 2,960 reporting entities by total reported value, about 1.4% of all industry payments in the dataset.

Does a payment from Regeneron Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.